GSK3B and nasopharyngeal carcinoma: To sum up, the targeted inhibition of β-catenin, Capn4, CBP, LHX2, FOXO3a, and the targeted activation of GSK3β in the targeted therapy of NPC could be a potential therapeutic strategy through the Wnt/β-catenin pathway.